Existing research has reported that multi‐targeted CDK inhibitors could restrain the activation of MYC in multiple myeloma cells48 and that MYC and UHRF2 were up‐regulated simultaneously in OS.49 The gene discussed is MYC; the disease is plasma cell myeloma.